Tuesday, December 7

**General Session 1**

*10:15 am*  
**GS1-05 Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study**  

*11:00 am*  
**GS1-08 CCTGMA.32, a phase III randomized double-blind placebo-controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438)**  

**2:00-5:00 Special Session**

**Trust in Science and Healthcare**  
Co-Moderator: Charles M. Perou, PhD  
University of North Carolina at Chapel Hill  
Chapel Hill, NC

Co-Moderator: Maimah Karmo  
Tigerlily Foundation  
Stone Ridge, VA

**Keynote #1**  
TBD

**Panel 1: Equity in Research and Patient Care**  
TBD

**Patient Advocates**  
Darcy Burbage, DNP, RN, AOCN  
Newark, DE

Na'Diah Smith  
Tigerlily Foundation

**Keynote #2**  
TBD

**Panel 2: Diversity in Clinical Trials – From Ideation to Implementation COVID Update**  
Erica Stringer-Reasor, MD  
UAB Medicine  
Birmingham, AL

Eric P. Winer, MD  
Dana-Farber Cancer Institute  
Boston, MA
Patient Advocates
Ashley Dedmon, MPH, CHES
Tigerlily Foundation

Ysabel Duron
The Latino Cancer Institute

5:00-6:00 Susan G. Komen® Brinker Awards for Scientific Distinction Lectures

Brinker Award for Scientific Distinction in Basic Science
Carlos Caldas, MD
University of Cambridge
Cambridge, United Kingdom

Brinker Award for Scientific Distinction in Clinical Research
Judy Garber, MD, MPH
Dana Farber Cancer Institute
Boston, MA

Wednesday, December 8
8:00-10:30 Poster Session 1

Spotlight Poster Discussion 1- Endocrine Resistance: Novel mechanisms and emerging new therapies
Chair: Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX

Luca Magnani, PhD
Imperial College London
London, United Kingdom

Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

General Session 2

9:45 am
GS2-01. Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2- breast cancer

~10:30 am
GS2-04. Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early-stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials

11:15 am
GS2-07. Distant-disease free interval in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and her2-negative (HER2-) breast cancer (BC) with recurrence score (RS) <
or = 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG s1007 (RxPONDER)

~11:45 am
GS2-09. Tamoxifen instigates uterine cancer development by activating PI3K signaling and supersedes PIK3CA driver mutations

*~12:00 pm
GS2-10. Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)

1:00-3:00 Special Sessions

Re-framing Leadership in Academic Breast Oncology post COVID-19
Co-Moderator: Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX

Co-Moderator: Rebecca Dent, MD, MSc
National Cancer Center Singapore
Singapore, Singapore

Learning by leading- lessons learned
Clifford A. Hudis, MD, FACP, FASCO
American Society of Clinical Oncology
Alexandria, VA

Applying the lessons of my mentor to building a successful translational breast program
TBD

Panel Members:
Lisa A. Carey, MD, ScM, FASCO
University of North Carolina at Chapel Hill
Chapel Hill, NC

Charles M. Perou, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC

Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Kornelia Polyak, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

4:00-6:00 Educational Sessions

Triple Negative Breast Cancer: Critical Update on Biology and Management
Moderator: Rita Nanda, MD
Genomic and transcriptomic landscape of TNBC
Zhi-Ming Shao, MD
Fudan University of Shanghai
Shanghai, China

Optimizing the management of early stage TNBC
Elizabeth A. Mittendorf, MD, PhD
Dana-Farber Brigham and Women's Cancer Center
Boston, MA

Management of special subtypes of TNBC
Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC

6:00-7:30 Spotlight Poster Discussions

Spotlight Poster Discussion 4 - Brain Metastases: Managing LMD / Targeting HER2
Chair: Andrew Brenner, MD
UT Health San Antonio
San Antonio, TX

Patricia Steeg, PhD
National Cancer Institute
Bethesda, MD

Eudocia Lee, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Thursday, December 9

8:00-9:30 Poster Session 3

Spotlight Poster Discussion 8 - Novel therapies for HER2+ disease
Chair: Ian E. Krop, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Optimizing use of HER2 therapies in metastatic HER2+ breast cancer and other subtypes
Priyanka Sharma, MD
University of Kansas Cancer Center
Westwood, KS

HER2 kinase inhibitors: neoadjuvant approaches and mechanisms of resistance
Cristina Saura Manich, MD
Vall d'Hebron University Hospital
Barcelona, Spain

Novel therapies for HER2+ advanced breast cancer
Jo Chien, MD
University California San Francisco
San Francisco, CA
**General Session 3**

11:45 am  
**GS3-09.** Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer  

12:00 pm  
**GS3-10.** Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)  

3:00 - 4:00 pm  
**TRANSLATIONAL SCIENCE FORUM**

**HER2 Heterogeneity**  
Matthew J. Ellis, MB, BChir, BSc., PhD, FRCP  
Baylor College of Medicine  
Houston, TX

**Basic**  
Kim RM Blenman, PhD, MS  
Yale Cancer Center  
Yale University  
New Haven, CT

**Heterogeneity in treatment outcomes for HER2+ breast cancer – Clinical management strategies**  
Sara M. Tolaney, MD, MPH  
Dana Farber Cancer Institute  
Boston, MA

**Molecular heterogeneity in HER2+ breast cancer – can outcomes be predicted?**  
Aleix Prat, MD, PhD  
Hospital Clinic Barcelona  
Barcelona, Spain

4:00-6:00 Educational Sessions

**Anti-cancer Immune Response**  
Moderator: Justin Balko, PharmD, PhD  
Vanderbilt University Medical Center  
Nashville, TN

**Understanding the anti-cancer immune response: Innate and adaptive responses to cancer cells**  
Laurence Zitvogel, MD, PhD  
Institut Gustave Roussy  
Villejuif, France

**Macro and micro: Macrophage and microbiome diversity in the breast cancer microenvironment**  
Jennifer L. Guerriero, PhD  
Dana-Farber Cancer Institute  
Harvard Medical School  
Boston, MA
Optimizing immunotherapy efficacy in the clinic through biomarkers: Advances in single cell and spatial histology analysis
Marleen Kok, MD, PhD
The Netherlands Cancer Institute
Amsterdam, Netherlands

6:00-7:30 Poster Session 4

Spotlight Poster Discussion 10 - Novel Immunotherapy Approaches - Stars at Night Ballroom 1&2
Chair: Kevin Kalinsky, MD, MS
Winship Cancer Institute
Emory University
Atlanta, GA

Rebecca A. Shatsky, MD
UC San Diego Health
San Diego, CA
TBD

Elizabeth A. Mittendorf, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Friday, December 10

8:00-9:30 Poster Session 5

Spotlight Poster Discussion 13 - Novel therapeutics
Chair: Sara M. Tolaney, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Mafalda Oliveira, MD, PhD
Vall d'Hebron Institute of Oncology
Barcelona, Spain

Heather A. Parsons, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

General Session 4

11:15 am GS4-07. The Breast PreCancer Atlas DCIS genomic signatures define biology and correlate with clinical outcomes: An analysis of TBCRC 038 and RAHT cohorts

11:45 am GS4-09. Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer
Ganz PA, Bandos H, Spanic T, Friedman S, Müller V, Kümmel S, Delaloge S, Brain E, Toi M, Yamauchi H,
12:30 – 1:30 pm  **DEBATE**

**RxPONDER: Was it all OFS?**
Chair: Harold Burstein MD, PhD
Dana-Farber Cancer Institute
Boston, MA

**Pro**
Michael Gnant, MD
Medical University of Vienna
Vienna, Austria

**Con**
Sibylle Loibl, Dr Med
GBG Forschungs GMBH
Hessen, Germany

3:00 – 4:00 pm  **Mini Symposia**

**The Evolution of Local Therapy in the Genomic Era**
Moderator: Tari King, MD
Brigham and Women's Hospital
Boston, MA

*Is less (or more) axillary surgery needed in the genomic era?*
Monica Morrow, MD
Memorial Sloan Kettering Cancer Center
New York, NY

*Can genomic risk be used to tailor radiation therapy?*
Philip Poortmans, PhD
Iridium Netwerk
Paris, France

6:00 – 8:00 pm  **View from the Trenches: What will You do on Monday Morning?**

Moderator: Stephen Johnston, MBBS, ARCP, PhD
The Royal Marsden Hospital
London, United Kingdom

**Panel Members**

Carlos H. Barrios, MD
Latin American Cooperative Oncology Group (LACOG)
Porto Alegre, Brazil

Thomas Braun, PhD
University of Michigan
Ann Arbor, MI

Javier Cortes, MD, PhD
International Breast Cancer Center
Barcelona, Spain

Erika Hamilton, MD
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN
### Poster Session 1 – Wednesday, December 8th 8-9:30 am

| **P1-02-02** | **Examination of low Her2 expression in breast cancer**  
| **P1-02-09** | **Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC)**  
| *P1-04-05* | **Multiplexed immunofluorescence staining of intra-tumoral immune cell populations and associations with immunohistochemical, clinical, and pathologic variables in breast cancer**  
| *P1-04-09* | **Essential role for MUC1-C in chronic activation of cytosolic nucleotide sensing and the type I interferon pathway in triple-negative breast cancer**  
| *P1-04-13* | **Generation and validation of an estrogen receptor signaling (ERS) gene panel that inversely correlates with antigen presentation and T cell infiltration and activity in hormone receptor positive (HR+) breast cancer**  
| **P1-08-35** | **Stromal tumor infiltrating lymphocytes analysis by race and ethnicity in triple negative breast cancers from 2 phase III randomized adjuvant breast cancer trials: ECOG-ACRIN E2197 and E1199**  
Klar N, Gray RJ, Adams S, Sparano JA, Goldstein LJ, DeMichele AM, Wolff AC, Davidson NE, George W Sledge GW, Badve SS. |
| P1-09-06 | Insulinemic potential of diet and risk of total and subtypes of breast cancer among US women
Romanos-Nanclares A, Willett WC, Rosner BA, Tamimi RM, Tabung FK, Holmes MD, Chen WY, Eliassen AH. |
| P1-18-02 | Sacituzumab Govitecan, in combination with the PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (mTNBC): translational investigation
| P1-18-12 | Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)
| P1-18-13 | Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC)
| P1-22-04 | Decision aids and risk prediction models to support decision making about DCIS treatment: A systematic literature review
| ~P1-23-01 | Male breast cancer- a 20-year multi-center experience
| **Poster Session 2 – Wednesday, December 8th 6–7:30 pm** |
| P2-01-15 | Developing highly sensitive high NGS data efficient ctDNA detection assays for breast cancer surveillance
Fu A, Cui W, Ton MV, Wang K, Gu W, Li T, Parsons HA, Liu MC, Sledge GW. |
| P2-07-02 | Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC)
| *P2-07-03 | Correlation of immune-related protein expression with hormone receptor (HR) status and pathologic response to neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) among patients with early-stage HER2+ breast cancer
| *P2-07-13 | High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlates of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-09-03</td>
<td>Pathogenic variants among female breast cancer patients with a subsequent cancer demonstrate preventable cancer burden</td>
</tr>
<tr>
<td></td>
<td>Bychkovsky BL, Lo M-T, Yussuf A, Horton C, Hemyari P, LaDuca H, Garber JE, Rana HQ.</td>
</tr>
<tr>
<td>P2-10-01</td>
<td>Estimating risk of breast cancer-specific mortality (BCSM) and non-BCSM in patients with triple-negative breast cancer</td>
</tr>
<tr>
<td>P2-11-21</td>
<td>Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model</td>
</tr>
<tr>
<td>P2-12-18</td>
<td>A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer</td>
</tr>
<tr>
<td></td>
<td>Lynce F, Yeh ED, Regan MM, Qin L, Bay CP, Krop I, Harrison BT, Nakhls F, Bellon J, Overmoyer B.</td>
</tr>
<tr>
<td>P2-13-02</td>
<td>Pathologic nodal staging and systemic therapy among patients with cT1-2N0 HER2+ breast cancer: A prospective single institution cohort analysis</td>
</tr>
<tr>
<td>P2-13-05</td>
<td>Central nervous system metastases as a site of first recurrence in adjuvant therapy trials of HER2+ early breast cancer (EBC)</td>
</tr>
<tr>
<td></td>
<td>Lin NU, Lueftner D, Bruksky AM, Tolane SM, Melisko ME, Holmes FA, Awada A.</td>
</tr>
<tr>
<td>P2-13-25</td>
<td>A phase I dose-escalation study of DHES0815A, a HER2-targeting antibody-drug conjugate with a DNA monoalkylator payload, in patients with HER2-positive breast cancer</td>
</tr>
<tr>
<td>P2-14-17</td>
<td>A phase 1b study of PVX-410 vaccine in combination with pembrolizumab in metastatic triple negative breast cancer (mTNBC)</td>
</tr>
<tr>
<td>P2-14-18</td>
<td>A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer</td>
</tr>
</tbody>
</table>

**Ongoing Trials Poster Session 1 – Wednesday, December 8th 6–7:30 pm**

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>OT1-12-02</td>
<td>Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab</td>
</tr>
<tr>
<td></td>
<td>Miller K, Emens LA, Tolane SM, Hurvitz SA, Hamilton E, Paton V, Hannah A, Boni V.</td>
</tr>
<tr>
<td>OT1-13-01</td>
<td>HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (trial in progress)</td>
</tr>
<tr>
<td></td>
<td>Hamilton E, Carey L, Ramos J, Chen Y, Krop I.</td>
</tr>
<tr>
<td>OT1-14-02</td>
<td>Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first line (1L), human epidermal growth factor receptor 2-positive</td>
</tr>
</tbody>
</table>


(HER2+) metastatic breast cancer (mBC): DESTINY-Breast09

*OT1-19-01 The metastatic breast cancer project: Generating the clinical and genomic landscape of metastatic breast cancer through patient-partnered research

Poster Session 3 – Thursday, December 9th

P3-03-04 Challenges of achieving high image quality on breast MRI for quantitative measurements in the I-SPY 2 TRIAL
Bareng TJ, Gibbs JE, Onishi N, Newitt DC, LeStage B, I-SPY 2 TRIAL Imaging Working Group, I-SPY 2 TRIAL Coordinators, Hylton NM.

P3-04-03 The value of screening MRI in patients with high-risk breast lesions: An observational single-institution cohort study

P3-08-01 Clonal hematopoiesis of indeterminate potential (CHIP) in metastatic triple negative breast cancer

P3-09-01 A ubiquitination cascade regulating the integrated stress response and survival in carcinomas

P3-09-18 The association between genomic alterations and body mass index in patients with early breast cancer

P3-12-01 Regular aspirin use, breast tumor characteristics and long-term breast cancer survival

P3-12-02 Loss of PTEN expression, PIK3CA mutations, and breast cancer survival in the Nurses’ health studies
Wang T, Heng YJ, Baker GM, Bret-Mounet VC, Hankinson SE, Holmes MD, Chen WY, Willett WC, Rosner BA, Tamimi RM, Eliassen AH.

P3-12-19 Associations of alcohol consumption with benign breast tissue composition

P3-12-32 Long-term outcomes among young Saudi women with breast cancer
Aboualkhair OA, Omair A, Masuadi E, Alamri G, Aljahani A, Alkushi A, Partridge A.

P3-15-03 Imaging and invasive lobular carcinoma: A survey study conducted by the lobular breast cancer alliance
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>OT2-01-02</td>
<td>Ongoing Trials Poster Session 2 – Thursday, December 9th 6–7:30 pm</td>
<td>First in human phase 1 dose escalation and expansion study of the safety and pharmacokinetics of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients with inoperable locally advanced or metastatic solid tumors, including breast cancer</td>
</tr>
<tr>
<td>OT2-11-05</td>
<td>SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable ESR1m who have not experienced disease progression on first-line therapy</td>
<td>Bidard F-C, Kalinsky K, Cristofanilli M, Bianchini G, Chia SKL, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, Walding A, Huang Bartlett C, Turner NC.</td>
</tr>
<tr>
<td>OT2-17-01</td>
<td>Randomized, multicenter, international phase 3 ARTEST study to evaluate the efficacy and safety of enobosarm versus active control for the treatment of AR+ ER+ HER2- metastatic breast cancer in patients who progressed on a nonsteroidal aromatase inhibitor, fulvestrant and CDK 4/6 inhibitor</td>
<td>Brufsky A, Linden H, Rugo H, Vogel C, O'Shaughnessy JA, Getzenberg RH, Barnette KG, Rodriguez D, Steiner MS, Mayer E.</td>
</tr>
</tbody>
</table>

**Poster Session 4 – Thursday, December 9th 6–7:30 pm**

| P4-04-06 | Integrative analysis of single-cell transcriptomic and spatial profiles characterized distinct tumor microenvironment phenotypes in hormone receptor positive (HR+) breast cancer | Shimada K, Cui YX, Goldberg JS, Pastorello R, Davis J, Vallius T, Kania L, Patel A, Moore M, Ogayoro ER, Dillon D, Sorger PK, Guerrero JL, Mittendorf EA. |
| P4-09-01 | Incidence of patient-reported fatigue developing in patients receiving palbociclib and endocrine therapy for advanced HR+ HER2- breast cancer | |
P4-10-01  Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05)

P4-10-02  Patient-reported outcomes in EA1131: A randomized phase III trial of platinum vs. capecitabine in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy

P4-11-01  Development of a clinico-bio-behavioral model for cancer-related fatigue (CRF) incorporating inflammatory biomarkers and proteomic data

P4-11-02  Prevalence and impact of fertility concerns in young women with breast cancer

P4-11-20  Attitudes and factors influencing contraception use over time in premenopausal women with early breast cancer in the prospective CANTO study

P4-12-01  Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial

Poster Session 5 – Friday, December 10th 8–9:30 am

P5-13-05  Multiplex spatial systems analysis of responses to spatially separate nanoliter doses of drug predicts systemic immune-modulating combination treatments in breast cancer
Tatarova Z, Blumberg DC, Coussens LM, Mills GB, Jonas O, Gray JW.

*P5-13-15  High dimensional flow cytometric analysis of the peripheral immune profile and response to HER2-targeted antibody therapy

P5-14-08  Effectiveness of palbociclib plus letrozole vs letrozole in US Hispanic and African American patients with metastatic breast cancer: Flatiron database analysis

P5-16-01  Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
Loibl S, Tolaney SM, Punie K, Oliveira M, Rugo HS, Bardia A, Hurviz SA, Bruksky A, Kalinsky KM,
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5-16-06</td>
<td>A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer</td>
<td>Cortes J, O'Shaughnessy J, Carey LA, Gianni L, Diéras V, Shi L, Gharabeh M, Preger L, Moore L, Phan S, Piccart M.</td>
</tr>
</tbody>
</table>

**Spotlight Sessions**

**Spotlight Session 1 – Wednesday, December 8th 8-9:30 am**

**PD1-05** Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer


**PD1-08** Erα1 mutant breast cancers show elevated basal cytokeratins and immune activation


**Spotlight Session 2 – Wednesday, December 8th 8-9:30 am**

~PD2-09 Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial

### Spotlight Session 4 – Wednesday, December 8th 6-7:30 pm

**PD4-02** Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study  

*~PD4-04* Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)  

*~PD4-05* Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases (BCBM)  

### Spotlight Session 5 – Wednesday, December 8th 6-7:30 pm

**PD5-06** Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline BRCA pathogenic variants having a pregnancy after breast cancer  

### Spotlight Session 6 – Wednesday, December 8th 6-7:30 pm

*~PD6-02* The metastatic breast cancer project - Expanding the clinical, genomic, and transcriptomic landscape of metastatic breast cancer through patient-partnered research  

*~PD6-03* Spatio-molecular dissection of the breast cancer metastatic microenvironment  

### Spotlight Session 7 – Thursday, December 9th 8-9:30 am

**PD7-06** Trends in surgical resection for stage IV breast cancer: Less surgery more systemic treatment  

**PD7-07** Surgical management and contralateral breast cancer risk in women with a history of radiation therapy for Hodgkin lymphoma: Results from a population-based cohort  
Eisenberg ER, Weiss A, Prakash I, Skamene S, Basik M, Boileau JF, Ajjamada L, Pollak M, Wong SM.

### Spotlight Session 9 – Thursday, December 9th 8-9:30 am

*~PD9-01* Expanding downstaging criteria in AJCC pathologic prognostic staging using OncotypeDx Recurrence Score® assay in T1-2N0 hormone-receptor positive patients enrolled in the TAILORx trial
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD9-02</td>
<td>Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or chemotherapy (chemo): The OXEL study</td>
</tr>
<tr>
<td>PD9-03</td>
<td>Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial (Alliance A011106)</td>
</tr>
</tbody>
</table>

**Spotlight Session 13 – Friday, December 10th 8-9:30 am**

*~PD13-10* Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors


**Spotlight Session 14 – Friday, December 10th 8-9:30 am**

PD14-08 Effectiveness of aromatase inhibitors versus tamoxifen in lobular compared to ductal carcinoma: Individual patient data meta-analysis of 9328 women with central histopathology, and 7654 women with e-Cadherin status